Core Insights - Kodiak Sciences Inc. is presenting KSI-101, a bispecific investigational biologic targeting macular edema secondary to inflammation, at the 2025 Congress of the International Ocular Inflammation Society in Rio de Janeiro [1][6] - The company aims to address the significant unmet need in treating macular edema caused by inflammation, which can lead to vision loss [3][4] Company Overview - Kodiak Sciences is a precommercial biotechnology company focused on developing therapeutics for retinal diseases, utilizing its ABC Platform for innovative drug design [8][9] - The company is advancing its pipeline, which includes three late-phase clinical assets expected to deliver Phase 3 topline data in 2026 [9] Product Details - KSI-101 is a high-strength (100 mg/mL) bispecific protein designed to target both interleukin-6 (IL-6) and vascular endothelial growth factor (VEGF), addressing the dual mechanisms of macular edema [6][5] - The ongoing Phase 1b study, APEX, is evaluating the safety and tolerability of KSI-101, with plans to progress into dual Phase 2b/3 studies [7]

Core Viewpoint - Kodiak Sciences Inc. has seen a 10.5% increase in share price over the past month, outperforming the S&P 500, but estimates have trended downward, indicating potential challenges ahead [1][2]. Group 1: Earnings and Estimates - The consensus estimate for Kodiak Sciences has shifted downward by 10.35% over the past month [2]. - The stock has a Zacks Rank of 3 (Hold), suggesting an expectation of in-line returns in the coming months [4]. Group 2: VGM Scores - Kodiak Sciences has a subpar Growth Score of D and a Momentum Score of F, with an overall aggregate VGM Score of F, placing it in the lowest quintile for investment strategies [3]. Group 3: Industry Performance - Kodiak Sciences is part of the Zacks Medical - Biomedical and Genetics industry, where Apellis Pharmaceuticals has gained 17.7% over the past month [5]. - Apellis Pharmaceuticals reported revenues of $166.8 million, reflecting a year-over-year decline of 3.2%, and is expected to post a loss of $0.44 per share for the current quarter, indicating a 57.1% change from the previous year [6].

Kodiak Sciences (KOD) 2025 Conference June 05, 2025 09:20 AM ET Speaker0 Here in New York. So Yeah. Here in New York. So it's good to be back here looking at the the summer. So we're close to midyear twenty twenty five. And at Kodiak, we have been very busy, and we have a number of activities in progress and a number of activities in in preparation. So it's an exciting time for Kodiak. It's exciting time, I think, for people to to look at us and to think about what our potential is As a company, we, of cour ...

Kodiak Sciences (KOD) incurred a loss of $1.09 per share in the first quarter of 2025, wider than the Zacks Consensus Estimate of a loss of 89 cents. The company had incurred a loss of 82 cents per share in the year-ago quarter.The company currently does not have any approved products in its portfolio. As a result, it is yet to generate revenues. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)KOD's Q1 Results in DetailResearch and development expenses were $43.6 million in the repo ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to _________ Commission File Number: 001-38682 KODIAK SCIENCES INC. (Exact Name of Registrant as Specified in its Charter) Delaware 27-0476525 (State ...

Exhibit 99.1 Kodiak Sciences Announces Recent Business Highlights and First Quarter 2025 Financial Results Palo Alto, CA — May 14, 2025 – Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the first quarter ended March 31, 2025. "In the first quarter of 2025, we maintained a strong focus on execution. We look forward to sharing our progress at an Investor R&D Update scheduled for July 16, 2025 at 1:00pm Eastern Time. We aim to demonstrate that our vision ...

PALO ALTO, Calif., May 14, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the first quarter ended March 31, 2025."In the first quarter of 2025, we maintained a strong focus on execution. We look forward to sharing our progress at an Investor R&D Update scheduled for July 16, 2025 at 1:00pm Eastern Time. We aim to demonstrate that our vision for Kodiak 2.0 as a precommercial stage retina focused biotech company with a maturing port ...

Core Viewpoint - Kodiak Sciences Inc. (KOD) has experienced significant selling pressure, resulting in a 28.1% decline over the past four weeks, but analysts anticipate improved earnings in the near future [1] Group 1: Technical Analysis - The Relative Strength Index (RSI) is a key indicator for identifying oversold stocks, with a reading below 30 typically indicating oversold conditions [2] - KOD's current RSI reading is 27.59, suggesting that the heavy selling may be exhausting itself, indicating a potential bounce back [5] Group 2: Fundamental Analysis - There is a strong consensus among sell-side analysts to raise earnings estimates for KOD, with a 3.3% increase in the consensus EPS estimate over the last 30 days [7] - An upward trend in earnings estimate revisions is generally associated with price appreciation in the near term [7] Group 3: Analyst Ratings - KOD holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, indicating a strong potential for a turnaround [8]

Core Viewpoint - Kodiak Sciences reported a narrower loss per share in Q4 2024 compared to the previous year, but the company has yet to generate any revenues and continues to face significant challenges in its operations [1][2][5]. Financial Performance - In Q4 2024, Kodiak Sciences reported a loss of $0.84 per share, which is an improvement from a loss of $1.13 per share in the same quarter of the previous year [1]. - For the full year 2024, the company recorded a loss per share of $3.35, which is better than the Zacks Consensus Estimate of a loss of $3.49 per share, compared to a loss of $4.97 per share in 2023 [5]. - Research and development expenses for Q4 2024 were $31.8 million, down 32% year over year, primarily due to reduced manufacturing activities and forfeitures of equity awards [3]. - General and administrative expenses were $14.4 million, down 14% year over year, mainly due to lower non-cash stock-based compensation expenses [3]. - As of December 31, 2024, the company had cash, cash equivalents, and marketable securities totaling $168.1 million, down from $197.9 million as of September 30, 2024, which is expected to support operations into 2026 [4]. Pipeline Developments - Kodiak is currently evaluating the efficacy and safety of tarcocimab in treatment-naïve patients with diabetic retinopathy in the phase III GLOW2 study, with top-line data expected in Q1 2026 [6]. - The company is also studying KSI-501, a dual inhibitor designed to target inflammation and abnormal angiogenesis in retinal vascular diseases, with top-line data from the phase III DAYBREAK study anticipated in Q2 2026 [7][9]. - Kodiak is enrolling patients in the phase Ib APEX study for its third investigational candidate, KSI-101, with updates expected in June 2025 [10][11]. Market Performance - Kodiak's shares have declined by 69.2% year-to-date, contrasting with the industry growth of 3.3% [4].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to _________ Commission File Number: 001-38682 KODIAK SCIENCES INC. WASHINGTON, DC 20549 FORM 10-K Title of each class Trading Symbol(s) Name of each exchange on which registered Common ...